Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT'AIDS cohort

被引:8
|
作者
Lions, C. [1 ]
Cabras, O. [2 ]
Cotte, L. [3 ]
Huleux, T. [4 ]
Gagneux-Brugnon, A. [5 ]
Makinson, A. [6 ,7 ]
Cabie, A. [8 ,9 ]
Bonnet, B. [10 ]
Duvivier, C. [11 ,12 ,13 ,14 ,25 ]
Hocqueloux, L. [15 ]
Cua, E. [16 ]
Cheret, A. [17 ,23 ]
Hustache-Mathieu, L. [18 ]
Obry-Roguet, V. [1 ]
Jacomet, C. [19 ]
Poizot-Martin, I. [1 ,20 ,21 ]
Drobacheff-Thiebaut, C.
Foltzer, A.
Bouiller, K.
Chirouze, C.
Lepiller, Q.
Bozon, F.
Babre, O.
Muret, P.
Laurichesse, H.
Lesens, O.
Vidal, M.
Mrozek, N.
Aumeran, C.
Baud, O.
Corbin, V.
Letertre, P.
Casanova, S.
Prouteau, J.
Hoen, B.
Lamaury, I.
Fabre, I.
Curlier, E.
Ouissa, R.
Schepers, K.
Herrmann-Storck, C.
Dournon, N.
Merrien, D.
Perre, P.
Guimard, T.
Bollangier, O.
Leautez, S.
Morrier, M.
Ader, F.
Biron, F.
机构
[1] Aix Marseille Univ, Hop St Marguerite, APHM, Serv Immunohematol Clin, Marseille, France
[2] CHU Bichat, Serv Malad Infect & Trop, Paris, France
[3] Hosp Civils Lyon, Serv Malad Infect & Trop, Lyon, France
[4] CH Tourcoing, Serv Univ Malad Infect & Voyageur, Tourcoing, France
[5] Univ Lyon, Serv Infectiol, CHU St Etienne, Grp Immunite Muqueuses & Agents Pathogenes,Inst P, Lyon, France
[6] Univ Hosp Montpellier, Infect & Trop Dis Dept, Montpellier, France
[7] Univ Montpellier, INSERM, UMI 233, U1175,IRD, Montpellier, France
[8] CHU Martinique, Serv Malad Infect & Trop, INSERM, CIC 1425, Fort De France, Martinique, France
[9] Univ Antilles, EA 4537, Basse Terre, Guadeloupe, France
[10] CHU HOTEL DIEU, Malad Infect & trop, Nantes, France
[11] Hop Necker Enfants Malad, APHP, Serv Malad Infect & Trop, Ctr Infectiol Necker Pasteur, F-75015 Paris, France
[12] Inst Pasteur, Ctr Med, Ctr Infectiol Necker Pasteur, F-75015 Paris, France
[13] Univ Paris 05, Sorbonne Paris Cite, Equipe Accueil, EA 7327, F-75015 Paris, France
[14] IHU Imagine, F-75015 Paris, France
[15] CHR Orleans La Source, Serv Malad Infect & Trop, Orleans, France
[16] CHU Nice, Serv Malad Infect & Trop, Nice, France
[17] CHU Kremlin Bicetre, AP HP, Serv Med Interne, Le Kremlin Bicetre, France
[18] CHU Besancon, Serv Malad Infect & Trop, Besancon, France
[19] CHU Clermont Ferrand, Serv Malad Infect & Trop, Clermont Ferrand, France
[20] Aix Marseille Univ, INSERM, IRD, SESSTIM,APHM St Marguerite,Clin Immunohematol Uni, Marseille, France
[21] Ctr Informat & Soins Immunodeficience Humaine & H, Immuno Hematol Unit, Serv Immunohematol Clin, 270 Blvd St Marguerite, F-13009 Marseille, France
[22] IHU, Marseille, France
[23] Bicetre, Paris, France
[24] Bichat, Paris, France
[25] Necker Pasteur, Paris, France
[26] La Pitie, Paris, France
关键词
Pre-exposure prophylaxis; PrEP; HIV; Missed opportunities; HIV testing; SEXUALLY-TRANSMITTED INFECTIONS; MEN; SEX; PEOPLE; PREP;
D O I
10.1186/s12879-019-3915-5
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
BackgroundHIV pre-exposure prophylaxis (PrEP) was implemented in France in November 2015 based on individual-level risk factors for HIV infection. We evaluated the proportion of missed opportunities for PrEP among newly HIV-diagnosed people entering the Dat'AIDS cohort in 2016.MethodsMulticenter retrospective analysis in 15 French HIV clinical centers of patients with a new diagnosis of HIV infection. Among them we differentiated patients according to the estimated date of infection: those occurring in the PrEP area (a previous negative HIV test in the last 12months or those with an incomplete HIV-1 western blot (WB) with no HIV-1 anti-Pol-antibody at time of HIV diagnosis) and those in the pre-PrEP area (older infections). Epidemiological, biological and clinical data at HIV diagnosis were collected. Clinicians retrospectively identified potential eligibility for PrEP based on individual-level risk factors for HIV infection among those infected in the PrEP area.ResultsAmong 966 patients with a new HIV diagnosis, 225 (23.3%) were infected in the PrEP area and 121 (53.8%) had complete data allowing evaluation of PrEP eligibility. Among them, 110 (91%) would have been eligible for PrEP, median age 31years, with 68 (75.6%) born in France and 10 (11.1%) in Central/West Africa, with more than one previous STI in 19 (15.7%). The main eligibility criteria for PrEP were being a man who had sex with men or transgender 91 (82.7%) with at least one of the following criteria: unprotected anal sex with 2 partners in the last 6months: 67 (60.9%); bacterial sexually transmitted infection in the last 12months: 33 (30%); Use of psychoactive substances in a sexual context (chemsex): 16 (14.5%). PrEP was indicated for other HIV risk factors in 25 (22.7%).ConclusionWith 91% (110/121) of patients infected in the PrEP area eligible for PrEP, this study highlights the high potential of PrEP in avoiding new infection in France but also shows a persistent delay in HIV testing. Thus, an important limit on PrEP implementation in France could be insufficient screening and care access.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Initiation of HIV pre-exposure prophylaxis in adolescents and young adults: Barriers and opportunities
    Mocorro, Igor
    Sandhu, Prabjot Jodie
    Rowniak, Stefan
    Leonard, Adam
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2021, 33 (09) : 700 - 708
  • [42] Pre-exposure prophylaxis HIV/AIDS mathematical model with non classical isolation
    Djomegni, P. M. Tchepmo
    Tekle, Andualem
    Dawed, Mohammed Y.
    JAPAN JOURNAL OF INDUSTRIAL AND APPLIED MATHEMATICS, 2020, 37 (03) : 781 - 801
  • [43] The future of HIV pre-exposure prophylaxis adherence: reducing barriers and increasing opportunities
    Haberer, Jessica E.
    Mujugira, Andrew
    Mayer, Kenneth H.
    LANCET HIV, 2023, 10 (06): : E404 - E411
  • [44] Roll-out and effectiveness of HIV pre-exposure prophylaxis in France: An overview
    de Gage, Sophie Billioti
    Jourdain, Hugo
    Desplas, David
    Dray-Spira, Rosemary
    THERAPIE, 2023, 78 (05): : 585 - 591
  • [45] Missed opportunities for HIV pre-exposure prophylaxis during a rapid scale-up program at Sydney Sexual Health Centre
    Atefi, David
    McIver, Ruthy
    Bourne, Christopher
    SEXUAL HEALTH, 2019, 16 (06) : 591 - 592
  • [46] Preparing for pre-exposure prophylaxis: perceptions and readiness of Canadian pharmacists for the implementation of HIV pre-exposure prophylaxis
    Yoong, Deborah
    Naccarato, Mark
    Sharma, Malika
    Wilton, James
    Senn, Heather
    Tan, Darrell H. S.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2016, 27 (08) : 608 - 616
  • [47] Pharmacists as providers of HIV pre-exposure prophylaxis
    Christine Bruno
    Parya Saberi
    International Journal of Clinical Pharmacy, 2012, 34 : 803 - 806
  • [48] HIV moments and pre-exposure prophylaxis Reply
    Dunn, David T.
    Gafos, Mitzy
    White, Ellen
    McCormack, Sheena
    LANCET, 2016, 387 (10027): : 1508 - 1508
  • [49] Pre-exposure prophylaxis as HIV prevention in the UK
    Brady, Michael
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2016, 7 (03) : 150 - 152
  • [50] Why Do HIV Pre-Exposure Prophylaxis Users Discontinue Pre-Exposure Prophylaxis Care? A Mixed Methods Survey in a Pre-Exposure Prophylaxis Clinic in Belgium
    Vanbaelen, Thibaut
    Rotsaert, Anke
    Jacobs, Bart K. M.
    Florence, Eric
    Kenyon, Chris
    Vuylsteke, Bea
    Laga, Marie
    Thijs, Reyniers
    AIDS PATIENT CARE AND STDS, 2022, 36 (04) : 159 - 167